Atrial natriuretic factor prohormone 31-67 - Madeleine Pharmaceuticals

Drug Profile

Atrial natriuretic factor prohormone 31-67 - Madeleine Pharmaceuticals

Alternative Names: Atrial natriuretic factor prohormone 31-67; MAD-001; MP-3167; Pro ANP 31-67; ProANF 31-67; Vastiras; Vessel dilator - Madeleine; VSDL - Madeleine

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Madeleine Pharmaceuticals
  • Developer Madeleine Pharmaceuticals; Medtronic
  • Class Heart failure therapies; Natriuretic peptides; Peptides
  • Mechanism of Action Atrial natriuretic factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Australia (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Australia (SC, Implant)
  • 01 Apr 2014 Phase-II clinical trials in Heart failure in Australia (SC, infusion & IV, infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top